Literature DB >> 3466165

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

K J Scanlon, E M Newman, Y Lu, D G Priest.   

Abstract

The human ovarian cell line A2780 was exposed to either cisplatin (10 microM) or 5-fluorouracil (5FUra) (5 microM) for 1 hr. Cytotoxicity was less than 14% with either agent alone. Cisplatin (10 microM) and 5FUra (5 microM) in combination for 1 hr caused a 76% reduction in cell growth. Thymidine (dThd, 10 microM), if given concomitantly with the combination of cisplatin and 5FUra, completely protected the tumor cells. A 30-min exposure to cisplatin increased the intracellular pools of 5,10-methylenetetrahydrofolate and tetrahydrofolate 2.5-fold. The capacity of intact cells to form 5-fluorodeoxyuridylate (FdUMP)-thymidylate (dTMP) synthase complex when incubated with fluorodeoxyuridine (FdUrd) was enhanced 2.5-fold when the cells were pretreated with cisplatin. These experiments demonstrate that cisplatin can increase the availability of the reduced folate necessary for tight binding of FdUMP to dTMP synthase, thus enhancing the cytotoxicity of the cisplatin and 5FUra combination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3466165      PMCID: PMC387045          DOI: 10.1073/pnas.83.23.8923

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Assay of intracellular free and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil.

Authors:  W L Washtien; D V Santi
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Actions of cis-diamminedichloroplatinum on cell surface nucleic acids in cancer cells as determined by cell electrophoresis techniques.

Authors:  D A Juckett; B Rosenberg
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

4.  Inhibition of serine metabolism by tetrahydrohomofolate in L1210 mouse leukemia cells.

Authors:  K J Scanlon; A R Cashmore; B A Moroson; R N Dreyer; J R Bertino
Journal:  Mol Pharmacol       Date:  1981-05       Impact factor: 4.436

5.  Interactions of platinum complexes with the essential and nonessential sulfhydryl groups of thymidylate synthetate.

Authors:  J L Aull; A C Rice; L A Tebbetts
Journal:  Biochemistry       Date:  1977-02-22       Impact factor: 3.162

6.  Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase.

Authors:  R G Moran; C P Spears; C Heidelberger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

7.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

8.  Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.

Authors:  J A Houghton; S J Maroda; J O Phillips; P J Houghton
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

9.  Comparison of folylpolyglutamate hydrolases of mouse liver, kidney, muscle and brain.

Authors:  D G Priest; C D Veronee; M Mangum; J M Bednarek; M T Doig
Journal:  Mol Cell Biochem       Date:  1982-03-19       Impact factor: 3.396

10.  Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

Authors:  S Shionoya; Y Lu; K J Scanlon
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

View more
  67 in total

Review 1.  Drug resistance in oncology: from concepts to applications.

Authors:  J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.

Authors:  G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy.

Authors:  Kenji Ina; Ryuichi Furuta; Takae Kataoka; Satoshi Kayukawa; Takashi Yoshida; Takaya Miwa; Yoshitaka Yamamura; Yuuki Takeuchi
Journal:  World J Clin Oncol       Date:  2011-10-10

Review 4.  Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus.

Authors:  Masami Minagawa; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

5.  Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma.

Authors:  Hidenari Nagai; Masahiro Kanayama; Katsuya Higami; Kouichi Momiyama; Akiko Ikoma; Naoki Okano; Katsuhiko Matsumaru; Manabu Watanabe; Koji Ishii; Yasukiyo Sumino; Kazumasa Miki
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

6.  Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Authors:  Yosuke Kumekawa; Kazuhiro Kaneko; Hiroaki Ito; Toshinori Kurahashi; Kazuo Konishi; Atsushi Katagiri; Taikan Yamamoto; Meiko Kuwahara; Yutaro Kubota; Takashi Muramoto; Yoshihide Mizutani; Michio Imawari
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

7.  Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.

Authors:  A Cassano; C Pozzo; D C Corsi; T Fontana; M R Noviello; A Astone; C Barone
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Changes in folate concentration in Yoshida sarcoma after administration of leucovorin or cisplatin.

Authors:  K Omura; T Misaki; T Hashimoto; E Kanehira; T Watanabe; F Ishida; Y Watanabe; T Shirasaka
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.

Authors:  J L Abbruzzese; R Amato; S Schmidt; M N Raber; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Yung-Chih Lai; Cheng-Yen Shih; Chin-Ming Jeng; Sien-Sing Yang; Jui-Ting Hu; Yung-Chuan Sung; Han-Ting Liu; Shaw-Min Hou; Chi-Hwa Wu; Tzen-Kwan Chen
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.